foxo4-dri senolytic peptide human trials FOXO4-DRI: Trial Status, Cancer Research & Data The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging PMC FOXO4 DRI Averix Labs FOX04 DRI (10mg) Nordsci FOXO4 DRI For Sale (10mg) Core Peptides Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9





